ITRMF · Iterum Therapeutics plc · Executive Compensation
$0.03
+0.01 (+34.78%)
At close · Jul 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“This condition raises substantial doubt about the Company's ability to continue as a going concern for one year from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Nov 14, 2025
Market Cap
$446
Shares
44.66M
Volume · Jul 21
18.8K
Avg daily vol (3M)
99.9K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Judith Matthews | Chief Financial Officer | Resigned | 2026-03-27 |
| Corey Fishman | President and Chief Executive Officer | Resigned | 2026-03-27 |
| Ronald M. Hunt | director of the Board | Resigned | 2025-03-10 |
| David Kelly | Chairman of the Board | Appointed | 2025-03-10 |
| Joseph J. Whalen | member of the Board | Appointed | 2025-03-10 |
| Ronald Hunt | Chairman and director | Resigned | 2025-02-14 |
| Sailaja Puttagunta M.D. | Chief Medical Officer | Resigned | 2024-05-31 |
| Sailaja Puttagunta | Chief Medical Officer | Resigned | 2024-05-10 |
| Mark Chin | member of the Board of Directors | Resigned | 2023-12-29 |